STI Stock Trade Intelligence
RGT

ARGENT BIOPHARMA LIMITED

Health Care · ASX:RGT
$0.0210
0.00%
Market cap
$2M
Turnover
$1,249
Last price
$0.0210
Day change
0.00%
Announcements
11
Range, past year
Open 0.082 · Low 0.017 · Now 0.021 · High 0.320
Open RGT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

RGT momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
21/100
Wyckoff phase
Downtrend14d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
+10.5%
1 Month
-22.2%
1 Year
-72.4%
RSI
39
Avg daily range
10.5%

ARGENT BIOPHARMA LIMITED scores 21 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 14 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -51.3%
  • High volatility (ATR 10.5%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

RGT announcements

Recent price-sensitive releases.
  • 2026-10-27 RGT Executes Global Licence for Non-Core Cannabis Genetics Progress Report
  • 2026-10-23 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-01 Execution of Loan Facility Agreement Debt Facility
  • 2026-09-29 Argent Signs NLC Licence to Expand Antiviral Portfolio Progress Report
  • 2026-08-31 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-26 FDA-CVM Establish INAD File for CannEpil Veterinary Program Progress Report
  • 2026-08-06 US Veterinary Development Programme for CannEpil Commences Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.